XOLACTA

Live / Allowed — First extension granted (statement of use) (as of 21 May 2026)

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 21 Feb 2024 filing date already counts against anyone who files later.

Record

Serial number
98414541
Mark type
Word mark
Filed
21 Feb 2024
Published for opposition
10 Dec 2024
Attorney of record
TARA PELAN

Goods and services

  • Class 005 — Pharmaceuticals: Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for use in treating cardiovascular, neurological, and inflammatory diseases and disorders, cancer, chronic wounds, tissue injuries, and radiation sickness, and as a radioprotectant against radiotherapy; drug delivery systems in the nature of exosomes for use in treating cardiovascular, neurological, and inflammatory diseases and disorders, cancer, chronic wounds, tissue injuries, and radiation sickness, and as a radioprotectant against radiotherapy; exosome-based drug delivery systems for use in treating cardiovascular, neurological, and inflammatory diseases and disorders, cancer, chronic wounds, tissue injuries, and radiation sickness, and as a radioprotectant against radiotherapy; exosomes for medical purposes for use in treating cardiovascular, neurological, and inflammatory diseases and disorders, cancer, chronic wounds, tissue injuries, and radiation sickness, and as a radioprotectant against radiotherapy; exosomes for therapeutic purposes for use in treating cardiovascular, neurological, and inflammatory diseases and disorders, cancer, chronic wounds, tissue injuries, and radiation sickness, and as a radioprotectant against radiotherapy; biological preparations comprising exosomes for use in treating cardiovascular, neurological, and inflammatory diseases and disorders, cancer, chronic wounds, tissue injuries, and radiation sickness, and as a radioprotectant against radiotherapy; synthetic peptides for the treatment of internal diseases and wounds for use in treating cardiovascular, neurological, and inflammatory diseases and disorders, cancer, chronic wounds, tissue injuries, and radiation sickness, and as a radioprotectant against radiotherapy; exosomes loaded with synthetic peptides for the treatment of internal diseases and wounds caused by cardiovascular, neurological, and inflammatory diseases and disorders, cancer, radiation sickness, and radiotherapy

Owner

Board proceedings on this mark

Prosecution history

  • 18 Sept 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 18 Sept 2026 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
  • 18 Sept 2026 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
  • 22 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 21 May 2026 — SOU EXTENSION 1 GRANTED
  • 21 May 2026 — SOU EXTENSION 1 FILED
  • 21 May 2026 — SOU TEAS EXTENSION RECEIVED
  • 25 Nov 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 20 Oct 2025 — TTAB RELEASE CASE TO TRADEMARKS
  • 20 Oct 2025 — OPPOSITION TERMINATED NO. 999999
  • 20 Oct 2025 — OPPOSITION DISMISSED NO. 999999
  • 09 Jun 2025 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
  • 09 Jun 2025 — OPPOSITION INSTITUTED NO. 999999
  • 09 May 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 09 May 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

View this trademark record on Rightsy